Labiotech.eu

News and Trends 3 Oct 2022

Oncopeptides starts European commercialization of myeloma drug in Germany

Swedish biotech company Oncopeptides AB has initiated the commercial launch of Pepaxti (melphalan flufenamide) in Germany. It marks the first market in Europe where the drug is being launched. On August 18, the European Commission granted Pepaxti, in combination with dexamethasone, Marketing Authorization in the European Union and countries in the European Economic Area, for […]

October 3, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 3 Oct 2022

Estrella and TradeUP merge to become publicly traded company

Estrella Biopharma, Inc. and TradeUP Acquisition Corp. have entered into a definitive business combination agreement that will result in Estrella becoming a publicly listed company. Upon closing of the transaction, TradeUP will be renamed Estrella Immunopharma, Inc. Estrella Biopharma is a preclinical-stage biopharmaceutical company developing CD19-targeted ARTEMIS T-cell therapies under certain license agreements with the […]

October 3, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 3 Oct 2022

FDA clears Kira Pharmaceuticals’ phase 2 trial for SLE-TMA treatment

Kira Pharmaceuticals says the US Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for KP104, a first-in-class bifunctional biologic that selectively and synergistically targets the alternative and terminal complement pathways. A phase 2 trial will evaluate the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of KP104 in participants with […]

October 3, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 3 Oct 2022

Oxford BioTherapeutics enters into antibody agreement with Genmab

Oxford BioTherapeutics (OBT) says Genmab has licensed a novel antibody related to one of OBT’s IO programs. The target was discovered using Oxford BioTherapeutics’ OGAP drug discovery platform, which incorporates one of the world’s largest proteomic databases, integrating clinical, experimental and expression data. Under the terms of the agreement, Genmab will be responsible for the […]

October 3, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 3 Oct 2022

Alexion, AstraZeneca Rare Disease to acquire genomic medicine company LogicBio Therapeutics

LogicBio Therapeutics, Inc. has entered into a definitive agreement under which Alexion, AstraZeneca Rare Disease (Alexion) will acquire LogicBio. The proposed acquisition brings LogicBio’s technology, experienced rare disease R&D team, and expertise in pre-clinical development to support Alexion’s growth in genomic medicines. Fred Chereau, president and chief executive officer at LogicBio, said: “We are excited […]

October 3, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 3 Oct 2022

Sierra Space and UC San Diego to develop first stem cell research institute in space

Sierra Space and University of California San Diego, one of the world’s top 15 research universities and a leader in microgravity research, have formed a new agreement with the goal of defining the future of human health care research in space. In a new memorandum of understanding between the two organizations, Sierra Space and UC […]

October 3, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 3 Oct 2022

Poxel granted orphan drug designation for kidney disease treatment

French biopharma company Poxel SA says the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to PXL770 for the treatment of patients with autosomal-dominant polycystic kidney disease (ADPKD). PXL770 is a novel, first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator – and is also a phase 2 ready ADPKD asset, subject […]

October 3, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 3 Oct 2022

Incyte to acquire Medicxi-backed Villaris Therapeutics to tackle vitiligo

Incyte has entered into an agreement to acquire Villaris Therapeutics, an asset-centric biopharmaceutical company seeded by Medicxi and focused on the development of novel antibody therapeutics for vitiligo. The deal could eventually be worth upwards of $1.4 billion. Its lead asset, auremolimab (VM6), an anti-IL-15Rβ monoclonal antibody (mAb), is expected to enter clinical development in […]

October 3, 2022 - 3 minutesmins - By Jim Cornall

CAR-T cell therapy, cancer therapy, cell therapy

News and Trends 3 Oct 2022

AmplifyBio acquires PACT Pharma assets

AmplifyBio has acquired select assets from PACT Pharma, Inc., a privately held biopharmaceutical company developing neoantigen-specific T cell receptor cell therapies. The deal will provide AmplifyBio with advanced characterization platforms, bioinformatics capabilities, and 40 drug development experts to enhance its own cell and gene therapy service offerings. AmplifyBio will also acquire the South San Francisco […]

October 3, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 3 Oct 2022

Redx presents data confirming anti-fibrotic effects of lung disease drug

Redx Pharma has announced preclinical efficacy data in immune mediated models for RXC007. The data on RXC007, its lead fibrosis asset, was presented alongside encouraging final phase 1 safety and pharmacokinetic data at the International Colloquium on Lung and Airway Fibrosis (ICLAF) on October 2 by Nicolas Guisot, research fellow at Redx Pharma. The data […]

October 3, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 3 Oct 2022

Roche launches next-generation SARS-CoV-2 Rapid Antibody Test

Roche has launched the SARS-CoV-2 Rapid Antibody Test 2.0 in markets accepting the CE Mark. The test is the next generation of Roche’s existing SARS-CoV-2 Rapid Antibody Test, which launched in July 2020. The SARS-CoV-2 Rapid Antibody Test 2.0 offers broader use than its original configuration, which focused on recovered patients, to now include vaccinated […]

October 3, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 30 Sep 2022

Treatment for hot flushes and night sweats accepted for regulatory review by EMA

A treatment for moderate to severe vasomotor symptoms (VMS) has been accepted by the European Medicines Agency (EMA) for regulatory review. Astellas Pharma Inc., submitted a marketing authorization application (MAA) for fezolinetant, an investigational oral, nonhormonal compound. VMS is characterized by hot flushes and/or night sweats which are common menopausal symptoms. Hot flushes The news […]

September 30, 2022 - 2 minutesmins - By Liza Laws

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Oncopeptides starts European commercialization of myeloma drug in Germany

Estrella and TradeUP merge to become publicly traded company

FDA clears Kira Pharmaceuticals’ phase 2 trial for SLE-TMA treatment

Oxford BioTherapeutics enters into antibody agreement with Genmab

Alexion, AstraZeneca Rare Disease to acquire genomic medicine company LogicBio Therapeutics

Sierra Space and UC San Diego to develop first stem cell research institute in space

Poxel granted orphan drug designation for kidney disease treatment

Incyte to acquire Medicxi-backed Villaris Therapeutics to tackle vitiligo

AmplifyBio acquires PACT Pharma assets

Redx presents data confirming anti-fibrotic effects of lung disease drug

Roche launches next-generation SARS-CoV-2 Rapid Antibody Test

Treatment for hot flushes and night sweats accepted for regulatory review by EMA

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!